A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors

Overview of attention for article published in European Journal of Medical Research, July 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 4 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 25 Mendeley

Summary X Wikipedia Dimensions citations

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 1,474 followers.

New article: A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors https://t.co/B6pBvuDd17 #kidneycancer #oncology https://t.co/nyuTU3qXJD

06 Jul 2022

Reply Repost Favourite

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. https://t.co/4uLLAY7xo0 https://t.co/XXutrvhy5A

05 Jul 2022

Reply Repost Favourite

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors https://t.co/q3ZslVxoGW https://t.co/u2iA5tFNo3

03 Jul 2022

Reply Repost Favourite

A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors https://t.co/l1q88VBwlY

03 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.